The long-term objective of this research program is to develop novel types of phosphoramidate-based anticancer drugs and evaluate their mechanisms of action and toxicity. This drug development program is based upon the design and synthesis of prodrug molecules that exploit unique chemistry for intracellular activation and release of active agents that could otherwise not penetrate the cell. This chemistry is especially well suited to the intracellular release of therapeutically relevant nucleotides and phosphotyrosine peptidomimetics, and the approach provides a strategy for the intracellular delivery of many novel drug candidates. Design and synthesis of prodrugs targeted to the SH2 domain represents a novel and potentially exciting application of this technology.
Specific aims to achieve our objectives include: 1) Complete the synthesis and mechanistic evaluation of novel indolequinone phosphoramidates; 2) Design, synthesize and evaluate novel nucleoside phosphoramidate prodrugs; and 3) Design, synthesize and evaluate a series of novel phosphotyrosine peptidomimetic prodrugs. New compounds will be evaluated both in vitro and in vivo using established assays to evaluate potential antitumor activity. New cell-based assays to measure disruption of SH2 domain interactions have been developed and will be applied to the evaluation of phosphotyrosine mimetic prodrugs. Promising candidates will be evaluated in human tumor xenograft models. The ultimate goal is to exploit the unique properties of phosphoramidate chemistry to develop new drugs that exhibit clinical efficacy against resistant or poorly responsive solid tumors.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Program Officer
Lees, Robert G
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Purdue University
Schools of Pharmacy
West Lafayette
United States
Zip Code
Huang, Rong; Oh, Hyunju; Arrendale, Allison et al. (2013) Intracellular targets for a phosphotyrosine peptidomimetic include the mitotic kinesin, MCAK. Biochem Pharmacol 86:597-611
Marian, Christine; Huang, Rong; Borch, Richard F (2011) Design and synthesis of a potential SH2 domain inhibitor bearing a stereodiversified 1,4-cis-enediol scaffold. Tetrahedron 67:10216-10221
Clark, Michelle K; Scott, Sarah A; Wojtkowiak, Jonathan et al. (2007) Synthesis, biochemical, and cellular evaluation of farnesyl monophosphate prodrugs as farnesyltransferase inhibitors. J Med Chem 50:3274-82
Choi, Jun Young; Borch, Richard F (2007) Highly efficient synthesis of enantiomerically enriched 2-hydroxymethylaziridines by enzymatic desymmetrization. Org Lett 9:215-8
Wu, Weidong; Sigmond, Jennifer; Peters, Godefridus J et al. (2007) Synthesis and biological activity of a gemcitabine phosphoramidate prodrug. J Med Chem 50:3743-6
Boutselis, Irene G; Yu, Xiao; Zhang, Zhong-Yin et al. (2007) Synthesis and cell-based activity of a potent and selective protein tyrosine phosphatase 1B inhibitor prodrug. J Med Chem 50:856-64
Garrido-Hernandez, Hugo; Moon, Kyung D; Geahlen, Robert L et al. (2006) Design and synthesis of phosphotyrosine peptidomimetic prodrugs. J Med Chem 49:3368-76
Wu, Weidong; Borch, Richard F (2006) Synthesis and biological activity of N-2,3-dihydroxypropyl-N-4-chlorobutyl nucleoside phosphoramidate prodrugs. Mol Pharm 3:451-6
Wu, Weidong; Freel Meyers, Caren L; Borch, Richard F (2004) A novel method for the preparation of nucleoside triphosphates from activated nucleoside phosphoramidates. Org Lett 6:2257-60
Tobias, Sandra C; Borch, Richard F (2004) Synthesis and biological evaluation of a cytarabine phosphoramidate prodrug. Mol Pharm 1:112-6

Showing the most recent 10 out of 32 publications